ReviewEuropean journal of haematology2017
Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.
Review in European journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.International journal of biological sciences · 2026Review
- Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer.Cancer biology & medicine · 2025Review
- Fabrication of Carbon Dots with Singlet Oxygen Generation and Their Potential Photodynamic Therapy Applications.Journal of fluorescence · 2025Article
- Sequential dual-targeting biomimetic nanovesicles for bone marrow-specific delivery of bortezomib in multiple myeloma.Frontiers in bioengineering and biotechnology · 2025Article
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Nanoparticle targeting of neutrophil glycolysis prevents lung ischemia-reperfusion injury.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study.Frontiers in cardiovascular medicine · 2024Article
- Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.Acta pharmacologica Sinica · 2023Article
- Nanoparticles in Medicine: Current Status in Cancer Treatment.International journal of molecular sciences · 2023Review
- Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.Journal of hematology & oncology · 2023Review
- Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles.Pharmaceutics · 2023Article
- E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma.Blood cancer journal · 2023Article
- Application Prospects of Triphenylphosphine-Based Mitochondria-Targeted Cancer Therapy.Cancers · 2023Review
- VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Characterization of ginsenoside compound K loaded ionically cross-linked carboxymethyl chitosan-calcium nanoparticles and its cytotoxic potential against prostate cancer cells.Journal of ginseng research · 2021Article
- MYC inhibitors in multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways.Theranostics · 2021Article
- Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.Nature communications · 2020Article
- Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multiple myeloma (MM) is a hematological malignancy that remains incurable, with relapse rates >90%. The main limiting factor for the effective use of chemotherapies in MM is the serious side effects caused by these drugs. The emphasis in cancer treatment has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted and rationally designed therapies showing greater efficacy and fewer side effects. Traditional chemotherapy has shown several disadvantages such as lack of targeting capabilities, systemic toxicity, and side effects; low therapeutic index, as well as most anticancer drugs, has poor water solubility. Nanoparticle delivery systems (NPs) are capable of targeting large doses of chemotherapies into the target area while sparing healthy tissues, overcoming the limitations of traditional chemotherapy. Here, we review the current state of the art in nanoparticle-based strategies designed to treat MM. Many nanoparticle delivery systems have been studied for myeloma using non-targeted NPs (liposomes, polymeric NPs, and inorganic NPs), triggered NPs, as well as targeted NPs (VLA-4, ABC drug transporters, bone microenvironment targeting). The results in preclinical and clinical studies are promising; however, there remains much to be learned in the emerging field of nanomedicine in myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.